News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|September 3, 2024

Luspatercept in Lower Risk MDS: Insights on the COMMANDS Trial

Author(s)Ryan Haumschild, PharmD, MS, MBA, James McCloskey, MD , Amer Zeidan, MD

Medical experts offer insights on the COMMANDS trial findings.

Episodes in this series

EP. 1 Advances in MDS Classification and Molecular Understanding

EP. 1 Advances in MDS Classification and Molecular Understanding

EP. 2 Choosing MDS Therapies: Risk-Based Approaches

EP. 2 Choosing MDS Therapies: Risk-Based Approaches

EP. 3 Luspatercept in Lower Risk MDS: Insights on the COMMANDS Trial

EP. 3 Luspatercept in Lower Risk MDS: Insights on the COMMANDS Trial

EP. 4 ASCERTAIN Data: Oral Decitabine-Cedazuridine Outcomes in MDS

EP. 4 ASCERTAIN Data: Oral Decitabine-Cedazuridine Outcomes in MDS

EP. 5 Oral vs. Injectable HMAs: Convenience and Efficacy in Higher Risk MDS

EP. 5 Oral vs. Injectable HMAs: Convenience and Efficacy in Higher Risk MDS

EP. 6 HMA Persistence and Effectiveness in Higher Risk MDS

EP. 6 HMA Persistence and Effectiveness in Higher Risk MDS

EP. 7 Innovations and Future Directions in Higher Risk MDS Treatments

EP. 7 Innovations and Future Directions in Higher Risk MDS Treatments

EP. 8 Oral vs. Injectable HMAs: Patient Perspectives, Access, and IRA Impact

EP. 8 Oral vs. Injectable HMAs: Patient Perspectives, Access, and IRA Impact

EP. 9 Oral vs. IV HMAs: Considerations and Patient Guidance

EP. 9 Oral vs. IV HMAs: Considerations and Patient Guidance

EP. 10 Patient Feedback for MDS: Insights and Closing Remarks

EP. 10 Patient Feedback for MDS: Insights and Closing Remarks

Video content above is prompted by the following:

Discuss the expanded indication of luspatercept in lower-risk myelodysplastic syndromes (based on the COMMANDS trial findings) and its implications for clinical practice.

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Latest CME

Innovations in Medicine: 2024 Lineup of New and Approved Specialty Drugs

Innovations in Medicine: 2024 Lineup of New and Approved Specialty Drugs

2.0 Credits / General Pharmacy

Revolutionizing Acute Pain Relief: Emerging Nonopioid Therapies and the Essential Role of Managed Care

AJMC Supplement

Revolutionizing Acute Pain Relief: Emerging Nonopioid Therapies and the Essential Role of Managed Care

2.0 Credits / Pain Management

Trending on AJMC

TrumpRx Launch Brings Savings—and Uncertainty

How Do GLP-1 Agonists Fit Into Stroke Care?

Addressing Disparities at Every Step of the Stroke Care Pathway: Luke Messac, MD, PhD

Aligning Treatment Goals in IgA Nephropathy: Applying KDIGO’s Dual-Pathway Framework to Clinical Decision-Making

5 Things to Know About the Oral GLP-1 Era

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

© 2025 MJH Life Sciences^®

All rights reserved.

Alt Text

Alt Text